Estudio en fase III, con enmascaramiento doble y aleatorizado de zolbetuximab en combinación con pembrolizumab y quimioterapia (CAPOX o mFOLFOX6) en el tratamiento de primera línea del adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado irresecable o metastásico en participantes cuyos tumores son HER2-negativo, Claudin (CLDN) 18.2 positivo y ligando de muerte programada 1 (PD-L1) positivo.

• Protocol code: 8951-CL-0305
• EudraCT code: No aplica
• Research group: Biomedical Research in Digestive Tract Tumors
• Service: Oncology
• Principal investigator:  Acosta Eyzaguirre, Daniel
• Pathology: Tumors
• Phase: Fase III

Estudio abierto, multicéntrico, en fase 1/2, de belumosudil en niños de 1 a <18 que requieren tratamiento sistémico para la enfermedad de injerto contra huésped crónica activa de moderada a grave (EICHc).

• Protocol code: DFI17893
• EudraCT code: No aplica
• Research group: Childhood Cancer and Blood Disorders
• Service: Pediatric Oncohematology
• Principal investigator:  Díaz de Heredia Rubio, Maria Cristina
• Pathology: Tumors
• Phase: Fase I

A phase III, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of Ravulizumab administered intravenously in adult participants at high risk of delayed graft function after kidney transplantation.

• Protocol code: ALXN1210-DGF-321
• EudraCT code: _
• Research group: Nephrology and kidney transplantation
• Service: Nephrology
• Principal investigator:  Moreso Mateos, Francesc
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III

An Open-label Phase 1/2 Multicentre Study to Evaluate the Safety, Tolerability and Efficacy of RTX001 Autologous Macrophages in Participants with Liver Cirrhosis who have Hepatic Decompensation (EMERALD)

• Protocol code: RTX001-002
• EudraCT code: No aplica
• Research group: Liver Diseases
• Service: Hepatology
• Principal investigator:  Pons Delgado, Mònica
• Pathology: Tumors
• Phase: Fase I

The RENAL LIFECYCLE trial; A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease

• Protocol code: 202100617
• EudraCT code: No aplica
• Research group: Nephrology and kidney transplantation
• Service: Nephrology
• Principal investigator:  Soler Romeo, Maria Jose
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III